Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Long-term Potentiation01:25

Long-term Potentiation

2.7K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when...
2.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

163
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
163
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

219
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
219
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

96
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
96

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigating naming error patterns after non-invasive brain stimulation and language treatment in persons with aphasia.

medRxiv : the preprint server for health sciences·2026
Same author

Inside Semantic Feature Analysis: A Within-Trial Analysis of Feature Quantity and Quality.

American journal of speech-language pathology·2026
Same author

Semantic and Phonological Brain Networks in Older Adults: A Systematic Scoping Review.

Brain sciences·2026
Same author

Revisiting Western Aphasia Battery-Revised in the Context of Mild Impairment.

American journal of speech-language pathology·2026
Same author

White matter predictors of cerebellar tDCS treatment effects in aphasia rehabilitation.

Frontiers in neurology·2026
Same author

Your Mileage May Vary: Individuals with Primary Progressive Aphasia Differ Widely in Their Utilization of Congruent Prosodic and Visual Information During Sentence Comprehension.

Brain sciences·2026

Related Experiment Video

Updated: Jun 5, 2025

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

17.8K

Augmenting Verb-Naming Therapy With Neuromodulation Decelerates Language Loss in Primary Progressive Aphasia.

Shannon M Sheppard1,2, Emily B Goldberg2, Rajani Sebastian3

  • 1Department of Speech and Hearing Sciences, University of Washington, Seattle.

American Journal of Speech-Language Pathology
|December 12, 2024
PubMed
Summary
This summary is machine-generated.

Verb Network Strengthening Treatment (VNeST) combined with transcranial direct current stimulation (tDCS) improved word finding in primary progressive aphasia (PPA). While VNeST alone helped trained verbs, adding tDCS enhanced untrained verb recall and other language skills.

More Related Videos

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia
08:48

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia

Published on: May 6, 2016

12.1K
Vagus Nerve Stimulation as a Tool to Induce Plasticity in Pathways Relevant for Extinction Learning
11:02

Vagus Nerve Stimulation as a Tool to Induce Plasticity in Pathways Relevant for Extinction Learning

Published on: August 21, 2015

23.3K

Related Experiment Videos

Last Updated: Jun 5, 2025

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia
10:15

Utilizing Repetitive Transcranial Magnetic Stimulation to Improve Language Function in Stroke Patients with Chronic Non-fluent Aphasia

Published on: July 2, 2013

17.8K
Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia
08:48

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia

Published on: May 6, 2016

12.1K
Vagus Nerve Stimulation as a Tool to Induce Plasticity in Pathways Relevant for Extinction Learning
11:02

Vagus Nerve Stimulation as a Tool to Induce Plasticity in Pathways Relevant for Extinction Learning

Published on: August 21, 2015

23.3K

Area of Science:

  • Neurolinguistics
  • Cognitive Neuroscience
  • Speech-Language Pathology

Background:

  • Primary progressive aphasia (PPA) is a neurodegenerative condition affecting language abilities.
  • Word-finding difficulties (anomia) are a common and debilitating symptom of PPA.
  • Current treatments for PPA symptoms, particularly anomia, have limited efficacy for sustained improvement.

Purpose of the Study:

  • To evaluate the efficacy of Verb Network Strengthening Treatment (VNeST) combined with left inferior frontal gyrus transcranial direct current stimulation (tDCS) in individuals with PPA.
  • To compare the effects of VNeST + real tDCS versus VNeST + sham stimulation on various language measures in PPA patients.

Main Methods:

  • A double-blind, within-subject, sham-controlled crossover design was employed with eight PPA participants.
  • Participants underwent two treatment phases: VNeST with real tDCS and VNeST with sham stimulation, each consisting of fifteen 1-hour sessions.
  • Language abilities, including trained/untrained verb naming, sentence production/comprehension, and discourse, were assessed at baseline and at 1 and 8 weeks post-treatment.

Main Results:

  • VNeST significantly improved trained verb naming and discourse completeness in both real tDCS and sham conditions at 1 week post-treatment.
  • Transcranial direct current stimulation (tDCS) augmentation led to generalized improvements in untrained verb naming, sentence production, and comprehension, persisting up to 8 weeks post-treatment.
  • Language abilities, specifically untrained verb naming and sentence comprehension, declined when VNeST was administered without tDCS.

Conclusions:

  • Combining VNeST with tDCS shows promise for enhancing word finding and other language functions in individuals with PPA.
  • VNeST alone can improve naming of trained verbs, but its benefits for untrained words may not be sustained without neuromodulation.
  • Further research with larger sample sizes is warranted to confirm the therapeutic potential of VNeST and tDCS for PPA treatment.